Ovid TherapeuticsOVID
Market Cap: $72.4M
About: Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
Employees: 40
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
188% more call options, than puts
Call options by funds: $23K | Put options by funds: $8K
6.29% less ownership
Funds ownership: 60.54% [Q1] → 54.25% (-6.29%) [Q2]
9% less funds holding
Funds holding: 80 [Q1] → 73 (-7) [Q2]
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
33% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 21
77% less capital invested
Capital invested by funds: $131M [Q1] → $29.6M (-$101M) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target | 194%upside $3 | Buy Reiterated | 19 Aug 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target | 194%upside $3 | Buy Reiterated | 26 Jul 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target | 194%upside $3 | Buy Reiterated | 2 Jul 2024 |
BTIG Thomas Shrader 40% 1-year accuracy 2 / 5 met price target | 390%upside $5 | Buy Maintained | 18 Jun 2024 |
B. Riley Securities Kalpit Patel 38% 1-year accuracy 5 / 13 met price target | 194%upside $3 | Buy Maintained | 18 Jun 2024 |
Financial journalist opinion
Based on 12 articles about OVID published over the past 30 days